Somewhat Positive News Coverage Somewhat Unlikely to Affect aTyr Pharma (LIFE) Share Price
News coverage about aTyr Pharma (NASDAQ:LIFE) has trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3805765693525 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of aTyr Pharma (NASDAQ:LIFE) remained flat at $$3.00 during trading hours on Monday. The company had a trading volume of 5,960 shares, compared to its average volume of 41,356. The company has a market cap of $89.28, a P/E ratio of -1.48 and a beta of 3.54. aTyr Pharma has a twelve month low of $2.30 and a twelve month high of $6.50. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17.
Several research firms have recently weighed in on LIFE. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Wednesday, February 28th. JPMorgan Chase & Co. downgraded shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Finally, ValuEngine downgraded shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $4.56.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-atyr-pharma-life-share-price/1909235.html.
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.